Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus BETAPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus BETAPAR.
ASMANEX HFA vs BETAPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Beta-2 adrenergic receptor agonist that stimulates adenylyl cyclase, increasing cAMP levels, leading to bronchodilation.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
Initial: 25 mg orally twice daily; may increase gradually to 100 mg twice daily based on tolerance and response.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 10-20 hours in severe renal impairment (CrCl <30 mL/min).
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; the remainder undergoes hepatic metabolism.
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid